Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...

At the ongoing International Society for Stem Cell Research meeting, Chinese researchers reported they demonstrated that SPT6 homolog, histone chaperone and transcription elongation factor (SPT6) ...

Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Urogen Pharma Ltd. plans to launch its new product July 1 after the firm overcame a decidedly mixed FDA advisory panel meeting to nail down approval June 12 of Zusduri (mitomycin, formerly known as ...

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...